Agilis Biotherapeutics Acquisition

7/23/2018

M&A

$200,000,000

Under the terms of the merger agreement, PTC will pay an upfront consideration of $50 million in cash and approximately $150 million in PTC common stock, subject to an estimated maximum 9.34 million share limit (with any shortfall to be made whole with additional cash consideration). In addition to the upfront payments, potential future consideration includes $60 million in development milestones to be paid over the next two years which includes the acceptance of a BLA. Additionally, the transaction includes up to $535 million in success-based milestones in connection with regulatory approvals on the three most advanced programs and receipt of a priority review voucher, as well as tiered commercial milestones of $150 million, and 2-6 % of annual net sales for Friedreich ataxia and Angelman syndrome.

Acquired or Merged

Biopharmaceutical

245 First St. Kendall Square 1800
Cambridge, MA 02142
USA

Agilis Biotherapeutics is focused on designing and engineering DNA-based therapeutics for life-threatening or fatal rare diseases.